Hisun In-Licenses China Rights to Celsion’s Cancer Drug for $100 Million
publication date: Jan 22, 2013
Zhejiang Hisun Pharma has in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal that totals $100 million in upfront and milestone payments. Celsion is expected to announce results from a Phase III trial of the drug later this month. In May 2012, Celsion chose Hisun as its global manufacturer for ThermoDox. Celsion expects the deal to be worth “hundreds of million of dollars” over time in milestones and royalties, given the prevalence of liver cancer in China. More details....
Stock Symbols: (SHA: 600267) (NSDQ: CLSN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.